STXBP1 is an important gene for normal brain function which plays a vital role in the process of nerve cells communication. STXBP1 is a very rare disorder caused by random changes in the gene (located in chromosome 9) leading to seizures, global developmental delay, motion impairments and most of the patients are nonverbal.
There are about 400 cases worldwide and according to a Danish study conducted in 2016 the disorder incidence in the population is about 1:92,000 (Stamberger et al., 2016). However as with other rare diseases there are probably additional cases that are yet to be diagnosed.
In most cases seizures appears from the first year and even from the first days of the patients' lives and according to several studies STXBP1 is one of the main genes leading to early onset epileptic encephalopathy (Allen et al., 2016, Helbig et al., 2016). In some cases patients may suffer from uncontrolled very frequent and severe seizures called Ohtahara syndrome, or from West syndrome which include stiffening seizures (spasms). Additional symptoms of STXBP1 disorder are global developmental delay, motion impairments including ataxia, dystonia and hypotonia. In large number of cases patients are not able to walk or sit unsupported. Some of the children are diagnose with autistic features and the majority of the patients are nonverbal.
Current treatments only targets the disorders' symptoms. Several dozen anti-epileptic drugs are used by different patients worldwide starting from the first days of their lives, some of these drugs may help control patients seizures while others won't. Children also receive allied health therapies including Physiotherapy (PT), Occupational therapy (OT), and Speech therapy (SLP) which may use communication boards or eye gazing system. Additional therapies includes Music therapy, Therapeutic horseback riding, Hydrotherapy and more. However, patients need supervision at all times and dependent on others for all day to day activities.
Who are we?
Currently there is no treatment for STXBP1 disorder however there are options! Several methods are being used worldwide to treat different rare disorders along with more common diseases. Some are in different pre-clinical research stages while others are tested in clinical trial. In addition several drugs have already been developed, approved and are used by patients.
Rare smile organization was founded by parents for a child with STXBP1 disorder in order to advance research for finding a treatment for children in Israel and worldwide. The organization act in several ways including fund raising for research along with the effort of raising awareness to the disorder among the scientific community, clinical community and general public. In addition the organization acts to collect relevant information that will contribute the research.
For bank transfer:
*After making the transfer please email us (firstname.lastname@example.org) in order to get a receipt
Mizrahi-Tefahot Bank Ltd
Branch 532, Park Hamada
Account number 165686
Rare smile (Hiuh Nadir) R.A. 580654523
IBAN code - IL500205320000000165686
SWIFT - MIZBILIT
Interested in update about our coming events and research progress?
Feel free to address us with any questions,suggestions etc.